Boundless Bio is bringing in $100 million from its IPO as the precision oncology company becomes the latest biotech to go public in 2024. The company has priced its 6.25 million shares at $16 apiece, ...
Boundless Bio’s announcement earlier this month of plans to go public was a sign that the biotech IPO window hadn’t slammed shut after a flurry of offerings at the start of the year. Now, the company ...
Chase welcome bonus for the Marriott Bonvoy Boundless® Credit Card allows new cardholders to earn five free nights after ...
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...
New platform connects high capacity leaders navigating high stakes inflection points with rigorously vetted human ...
Discontinuing current monotherapy and combination arms of BBI-355 in POTENTIATE clinical trial. Plans to evaluate BBI-355 and BBI-825 as a combination therapy in the POTENTIATE clinical trial, ...
Targeted therapies and immunotherapies offer new treatment options for more types of cancer, but these drugs are less helpful when tumors produce multiple copies of a gene. This gene amplification ...
Boundless Publishing Group and its imprint Neem Tree Press entered liquidation and stopped conducting business as of Friday, ending a months-long effort to rescue the assets of failed crowdfunding ...
I Am Boundless, Inc. launched its #BoundlesslyBeautiful campaign to promote inclusivity and to challenge societal beauty standards. The event aimed to empower the women, to give them a voice and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results